Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone919-806-1074
Debt
Current Ratio19.91
Quick Ratio19.91
Price-To-Earnings
Sales & Book Value
Annual Sales$4.49 million
Price / Sales34.68
Price / Cash FlowN/A
Price / Book0.65
Profitability
Net Income$-70,980,000.00
Net Margins-1,752.41%
Return on Assets-34.61%
Miscellaneous
Employees82
OptionableOptionable
Chimerix (NASDAQ:CMRX) Frequently Asked Questions
What is Chimerix's stock symbol?
Chimerix trades on the NASDAQ under the ticker symbol "CMRX."
How were Chimerix's earnings last quarter?
Chimerix Inc (NASDAQ:CMRX) posted its earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.09. The biopharmaceutical company had revenue of $0.37 million for the quarter, compared to the consensus estimate of $0.97 million. Chimerix had a negative net margin of 1,752.41% and a negative return on equity of 36.40%. View Chimerix's Earnings History.
When is Chimerix's next earnings date?
What price target have analysts set for CMRX?
3 brokers have issued 12-month target prices for Chimerix's shares. Their predictions range from $6.00 to $10.00. On average, they expect Chimerix's share price to reach $8.00 in the next year. This suggests a possible upside of 160.6% from the stock's current price. View Analyst Price Targets for Chimerix.
What is the consensus analysts' recommendation for Chimerix?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Chimerix.
What are Wall Street analysts saying about Chimerix stock?
Here are some recent quotes from research analysts about Chimerix stock:
- 1. According to Zacks Investment Research, "Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. " (1/3/2019)
- 2. HC Wainwright analysts commented, "We base our $10 price target on probability-adjusted revenue forecasts for brincidofovir in AdV, smallpox and multiviral prevention. We use the net present value of our revenue forecast through 2026, apply a 15% POS for brincidofovir in AdV and other viruses, a 35% POS for brincidofovir in smallpox, a 4x price/sales multiple, value the early stage pipeline at $1.56/share and 2Q18 fully diluted net cash of $4.08/share to arrive at our $10 price target. Our P/S multiple of 4x is in line with Chimerix’s peers that range between 2-5x." (9/7/2018)
Has Chimerix been receiving favorable news coverage?
Media stories about CMRX stock have trended positive recently, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Chimerix earned a daily sentiment score of 2.8 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 7.0 out of 10, indicating that recent news coverage is likely to have an impact on the stock's share price in the next several days.
Are investors shorting Chimerix?
Chimerix saw a drop in short interest in December. As of December 31st, there was short interest totalling 373,932 shares, a drop of 40.1% from the December 14th total of 623,801 shares. Based on an average daily trading volume, of 699,283 shares, the days-to-cover ratio is presently 0.5 days. Approximately 0.8% of the company's shares are sold short. View Chimerix's Current Options Chain.
Who are some of Chimerix's key competitors?
Some companies that are related to Chimerix include Viking Therapeutics (VKTX), Cara Therapeutics (CARA), Karyopharm Therapeutics (KPTI), Crinetics Pharmaceuticals (CRNX), Aptinyx (APTX), MacroGenics (MGNX), CymaBay Therapeutics (CBAY), ProQR Therapeutics (PRQR), AMAG Pharmaceuticals (AMAG), Arvinas (ARVN), Collegium Pharmaceutical (COLL), Assembly Biosciences (ASMB), Innate Pharma (IPHYF), Zymeworks (ZYME) and NuCana (NCNA).
Who are Chimerix's key executives?
Chimerix's management team includes the folowing people:
- M. Michelle Berrey, President, Chief Executive Officer & Director
- Timothy W. Trost, Chief Financial Officer, Secretary & Senior VP
- Randall Lanier, Chief Science Officer
- Roy W. Ware, Chief Technology & Manufacturing Officer
- Joseph F. Rutledge, Chief Information Officer & VP-IT
How do I buy shares of Chimerix?
Shares of CMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Chimerix's stock price today?
One share of CMRX stock can currently be purchased for approximately $3.07.
How big of a company is Chimerix?
Chimerix has a market capitalization of $151.16 million and generates $4.49 million in revenue each year. The biopharmaceutical company earns $-70,980,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis. Chimerix employs 82 workers across the globe.
What is Chimerix's official website?
How can I contact Chimerix?
Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-806-1074 or via email at [email protected]
MarketBeat Community Rating for Chimerix (NASDAQ CMRX)
MarketBeat's community ratings are surveys of what our community members think about Chimerix and other stocks. Vote "Outperform" if you believe CMRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CMRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
